抄録
Experimental and clinical studies were carried out on latamoxef (LMOX), a synthetic antibiotic of the oxacephem group, with the following results.
1) To test antibacterial activity, MIC was measured for 208 strains of 20 species, isolated clinically and kept in our department, and in the same time MIC of CEZ, CMZ and CPZ also was measured as control drugs. The results indicated that LMOX was far inferior to other drugs against gram-positive bacteria but far superior against gram-negative bacteria.
2) The concentrations in serum and the tissue of the oral cavity were measured by means of bioassay in 21 cases of oral surgery and 1 case of infection with abcess formation after d.i. of LMOX 1g for 1 hour and successive testing of the serum and tissue from the oral cavity. The concentration in the serum showed an average of 57.4μg/ml at the end of drip infusion and 6.0μ/ml 360 minutes after the start. The concentration in the tissue showed a transfer of 20-40% from the serum in the gingiva and mucosa at the end of drip infusion and approximately 10% in the mandibular bone.
3) A clinical study was made in 19 cases of acute oral infection. The rate of effective ness was 79.0%. A slight increase in GOT and GPT was noted as a side effects in 2 cases.
4) The results with regard to anti-bacterial registance to gram-positive bacteria were worse than those for other substances in fundamental studies, but clinically LMOX was effective.
While LMOX is undoubtedly a superior antibiotic, in the oral cavity it is more appropriate for application to intractable secondary infection and relatively serious delayed infections than for primary infections.
